SIA
IOVA icon

SkyView Investment Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

SkyView Investment Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,000
Closed -$188K – 320
2024
Q3 		$188K Buy
+20,000
New +$189K 0.03% 219

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

SkyView Investment Advisors's IOVA Position: Q4 2024 in Review

SkyView Investment Advisors sold out of Iovance Biotherapeutics (IOVA) in Q4 2024, closing a stake of 20,000 shares — an estimated $188K sold.

SkyView Investment Advisors first reported a position in IOVA in Q3 2024 and held it in 1 quarter. The position peaked at $188K in Q3 2024. 301 funds tracked by Wall St. Rank hold IOVA as of Q4 2024.

  • SkyView Investment Advisors reported no remaining Iovance Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • SkyView Investment Advisors sold 20,000 Iovance Biotherapeutics shares in Q4 2024, an estimated $188K.
  • SkyView Investment Advisors first reported a position in Iovance Biotherapeutics in Q3 2024 and held it in 1 quarter.
  • SkyView Investment Advisors's Iovance Biotherapeutics position peaked at $188K in Q3 2024.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2024.

Based on SkyView Investment Advisors's 13F filing for Q4 2024, filed 2 Jun 2025.